Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study

被引:17
作者
Valentin, Julie [1 ]
Ferte, Thomas [2 ]
Dorizy-Vuong, Valerie [1 ]
Dousset, Lea [1 ,3 ]
Prey, Sorilla [1 ,3 ]
Dutriaux, Caroline [1 ,3 ]
Pham-Ledard, Anne [1 ,4 ]
Beylot-Barry, Marie [1 ,4 ]
Gerard, Emilie [1 ]
机构
[1] Univ Hosp Bordeaux, Hosp St Andre, Dept Dermatol, Bordeaux, France
[2] Bordeaux Hosp Univ Ctr, Pole Sane Publ, Serv Informat Med, Unite Informat & Archivist Med, F-33000 Bordeaux, France
[3] Univ Bordeaux, INSERM, U1035, F-33076 Bordeaux, France
[4] Univ Bordeaux, Bordeaux Res Translat Oncol, Team Oncogenesis Cutaneous Lymphomas 3, INSERM,U1053, Bordeaux, France
关键词
PATIENTS PTS; PEMBROLIZUMAB; OUTCOMES; RESISTANCE; CESSATION; BLOCKADE; THERAPY; IPILIMUMAB; EFFICACY; SAFETY;
D O I
10.1155/2021/5524685
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Anti-PD-1 has dramatically improved the survival of patients with advanced melanoma. However, there is a lack of data on maintenance of the response after treatment discontinuation. We aimed to evaluate the progression-free survival (PFS) of patients with metastatic melanoma after anti-PD-1 interruption for objective response (OR) or limiting toxicity during clinical trials. Methods. All patients with advanced melanoma who stopped single-agent anti-PD-1 antibodies for objective response or toxicity were included between April 2014 and January 2019 in our institution (data cut-off, September 10th, 2019). Clinical and biological factors associated with relapse were studied. Results. The median follow-up after introduction of treatment was 36.5 months [4.6-62.4], and the median follow-up after discontinuation of treatment was 15.7 months (2.5-45.1). Out of 65 patients, 28 patients stopped immunotherapy for limiting adverse effects (AEs) (43.1%), 25 for complete response (CR) (38.4%), and 12 for partial response (PR) or long-term stable disease (SD) (18.5%). Twelve patients relapsed (18.5%) after a median time of 9 months [1.9-40.9 months]. Seven relapsed after discontinuation for AEs, 3 after discontinuation for CR, and 2 after discontinuation for PR/SD. The median PFS after therapy discontinuation was not reached. No statistical association was found between recurrence and age, sex, increased LDH, BRAF status, presence of brain metastases, previous treatments, radiotherapy, or time on anti-PD-1 treatment. Conclusion. This cohort shows a global recurrence rate of 18.5% and confirms a long-lasting response after anti-PD-1 cessation regardless of the cause of discontinuation.
引用
收藏
页数:8
相关论文
共 25 条
[11]   Considerations for treatment duration in responders to immune checkpoint inhibitors [J].
Marron, Thomas U. ;
Ryan, Aideen E. ;
Reddy, Sangeetha M. ;
Kaczanowska, Sabina ;
Younis, Rania H. ;
Thakkar, Dipti ;
Zhang, Jiajia ;
Bartkowiak, Todd ;
Howard, Rachel ;
Anderson, Kristin G. ;
Olson, Daniel ;
Naqash, Abdul Rafeh ;
Patel, Ravi B. ;
Sachdev, Esha ;
Rodriguez-Ruiz, Maria E. ;
Sheffer, Michal ;
Church, Sarah ;
Fuhrman, Christopher ;
Overacre-Delgoffe, Abigail ;
Nguyen, Rosa ;
Florou, Vaia ;
Thaxton, Jessica E. ;
Aggen, David H. ;
Guerriero, Jennifer L. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
[12]   Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study [J].
McArthur, Grant A. ;
Chapman, Paul B. ;
Robert, Caroline ;
Larkin, James ;
Haanen, John B. ;
Dummer, Reinhard ;
Ribas, Antoni ;
Hogg, David ;
Hamid, Omid ;
Ascierto, Paolo A. ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
O'Day, Stephen J. ;
Kirkwood, John M. ;
Eggermont, Alexander M. ;
Dreno, Brigitte ;
Sosman, Jefferey A. ;
Flaherty, Keith T. ;
Yin, Ming ;
Caro, Ivor ;
Cheng, Suzanne ;
Trunzer, Kerstin ;
Hauschild, Axel .
LANCET ONCOLOGY, 2014, 15 (03) :323-332
[13]   Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy [J].
Mesnard, C. ;
Bodet-Milin, C. ;
Eugene, T. ;
Nguyen, J-M ;
Khammari, A. ;
Dreno, B. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (10) :2261-2267
[14]   Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab [J].
Nomura, Motoo ;
Otsuka, Atsushi ;
Kondo, Tomohiro ;
Nagai, Hiroki ;
Nonomura, Yumi ;
Kaku, Yo ;
Matsumoto, Shigemi ;
Muto, Manabu .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (05) :999-1004
[15]   The blockade of immune checkpoints in cancer immunotherapy [J].
Pardoll, Drew M. .
NATURE REVIEWS CANCER, 2012, 12 (04) :252-264
[16]   Loss of functional beta(2)-microglobulin in metastatic melanomas from five patients receiving immunotherapy [J].
Restifo, NP ;
Marincola, FM ;
Kawakami, Y ;
Taubenberger, J ;
Yannelli, JR ;
Rosenberg, SA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (02) :100-108
[17]   Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study [J].
Robert, Caroline ;
Ribas, Antoni ;
Schachter, Jacob ;
Arance, Ana ;
Grob, Jean-Jacques ;
Mortier, Laurent ;
Daud, Adil ;
Carlino, Matteo S. ;
McNeil, Catriona M. ;
Lotem, Michal ;
Larkin, James M. G. ;
Lorigan, Paul ;
Neyns, Bart ;
Blank, Christian U. ;
Petrella, Teresa M. ;
Hamid, Omid ;
Su, Shu-Chih ;
Krepler, Clemens ;
Ibrahim, Nageatte ;
Long, Georgina, V .
LANCET ONCOLOGY, 2019, 20 (09) :1239-1251
[18]   Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma [J].
Robert, Caroline ;
Ribas, Antoni ;
Hamid, Omid ;
Daud, Adil ;
Wolchok, Jedd D. ;
Joshua, Anthony M. ;
Hwu, Wen-Jen ;
Weber, Jeffrey S. ;
Gangadhar, Tara C. ;
Joseph, Richard W. ;
Dronca, Roxana ;
Patnaik, Amita ;
Zarour, Hassane ;
Kefford, Richard ;
Hersey, Peter ;
Zhang, Jin ;
Anderson, James ;
Diede, Scott J. ;
Ebbinghaus, Scot ;
Hodi, F. Stephen .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1668-+
[19]   Pembrolizumab versus Ipilimumab in Advanced Melanoma [J].
Robert, Caroline ;
Schachter, Jacob ;
Long, Georgina V. ;
Arance, Ana ;
Grob, Jean Jacques ;
Mortier, Laurent ;
Daud, Adil ;
Carlino, Matteo S. ;
McNeil, Catriona ;
Lotem, Michal ;
Larkin, James ;
Lorigan, Paul ;
Neyns, Bart ;
Blank, Christian U. ;
Hamid, Omid ;
Mateus, Christine ;
Shapira-Frommer, Ronnie ;
Kosh, Michele ;
Zhou, Honghong ;
Ibrahim, Nageatte ;
Ebbinghaus, Scot ;
Ribas, Antoni .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2521-2532
[20]   Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib [J].
Robert, Caroline ;
Karaszewska, Boguslawa ;
Schachter, Jacob ;
Rutkowski, Piotr ;
Mackiewicz, Andrzej ;
Stroiakovski, Daniil ;
Lichinitser, Michael ;
Dummer, Reinhard ;
Grange, Florent ;
Mortier, Laurent ;
Chiarion-Sileni, Vanna ;
Drucis, Kamil ;
Krajsova, Ivana ;
Hauschild, Axel ;
Lorigan, Paul ;
Wolter, Pascal ;
Long, Georgina V. ;
Flaherty, Keith ;
Nathan, Paul ;
Ribas, Antoni ;
Martin, Anne-Marie ;
Sun, Peng ;
Crist, Wendy ;
Legos, Jeff ;
Rubin, Stephen D. ;
Little, Shonda M. ;
Schadendorf, Dirk .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (01) :30-39